Pharmaceutical Sales: 100% (2026)

TOP 3 Markets:

1. India: 65%
2. Southeast Asia: 20%
3. Middle East and North Africa (MENA): 10%

AstraZeneca Pharma India Limited generates all its sales from the pharmaceutical industry. The Indian market is the most significant for the company as it accounts for the majority of sales. This is due to the strong presence and established distribution channel in India.

Southeast Asia and the MENA region are also important markets, accounting for 30% of sales together. These regions offer growth opportunities due to the increasing demand for healthcare solutions and the rising investments in healthcare.

Production Sites: Bangalore, India

AstraZeneca Pharma India Limited mainly produces its products in Bangalore. The production facility there is one of the most important for the company and plays a central role in the manufacturing and delivery of pharmaceutical products for the Indian market.

The company continuously invests in modernizing and expanding its production capacities to meet the increasing demands and ensure the quality of its products.

Strategic Focus Points:

• Research and Development: Increase investments in R&D by 20% (2025)
• Market Expansion: Targeted expansion in emerging markets
• Sustainability: Introduction of environmentally friendly production processes by 2030

AstraZeneca Pharma India Limited is pursuing a multi-pronged growth strategy that heavily emphasizes innovation and expansion. The company has significantly increased its investments in research and development to develop new drugs and enhance existing therapies. This is intended not only to strengthen the product pipeline but also to solidify the market position in India and internationally.

In addition, there is a strategic focus on expanding into emerging markets, where the company sees a growing demand for affordable and effective medications. These markets offer significant growth potential that AstraZeneca aims to capitalize on through targeted market entry strategies.

Another key aspect of the growth strategy is sustainability. AstraZeneca has committed to making its production processes more environmentally friendly by 2030, aiming to reduce the ecological footprint and enhance the company's image. This aligns with the global trend towards greater sustainability in the pharmaceutical industry.

Main raw materials: Active pharmaceutical ingredients (APIs), excipients, packaging materials
Countries of origin: USA, China, Germany, Switzerland

AstraZeneca Pharma India Limited mainly imports active pharmaceutical ingredients (APIs) that are essential for the production of their pharmaceutical products. These APIs are often sourced from the USA and China, as these countries are significant manufacturers of APIs.

In addition, excipients and packaging materials are imported to support the production and distribution of the medications. Germany and Switzerland are also important partner countries that supply high-quality pharmaceutical materials.

This import strategy enables AstraZeneca to produce high-quality products and at the same time benefit from global supply chains.

Market share in India: 5% (estimated 2026)
R&D expenses: 12% of revenue (2025)
Product diversification: Over 30 products in the portfolio (2026)

AstraZeneca Pharma India Limited has a significant competitive advantage through its strong research and development, accounting for approximately 12% of revenue. This enables the company to continuously bring innovative products to the market and differentiate itself from competitors.

The company also benefits from a diversified product portfolio with over 30 products, minimizing the risk of dependencies on individual drugs. This diversification strengthens the market position and allows AstraZeneca to address various health needs.

Despite an estimated market share of 5% in India, which is moderate compared to some local competitors, AstraZeneca remains in an advantageous position to capitalize on future growth opportunities due to its global brand presence and strong pipeline.

Institutional Investor Share: 30% (estimated for 2026)

Insider Buys/Sells: No significant transactions in the last year (2025)

The institutional investor share in AstraZeneca Pharma India Limited is estimated to be around 30%. This reflects the confidence of institutional investors in the company's long-term performance.

In 2025, there were no significant insider buys or sells, indicating that the management and other insiders have confidence in the stability and future prospects of the company. Such transactions are often seen as an indicator of the management's assessment of the company's value.

Market share of AstraZeneca Pharma India Limited: Estimated 3-5% (2026)

Top competitors and their market shares:

1. Sun Pharmaceutical Industries Ltd.: 8-10%
2. Cipla Ltd.: 7-9%
3. Dr. Reddy's Laboratories Ltd.: 6-8%
4. Lupin Ltd.: 5-7%
5. Aurobindo Pharma Ltd.: 4-6%
6. AstraZeneca Pharma India Limited: 3-5%
7. Torrent Pharmaceuticals Ltd.: 3-4%
8. Zydus Lifesciences Ltd.: 3-4%
9. Alkem Laboratories Ltd.: 2-3%
10. Glenmark Pharmaceuticals Ltd.: 2-3%

Moat of AstraZeneca Pharma India Limited:

AstraZeneca Pharma India Limited has a moderate moat, mainly supported by its strong research and development as well as its innovative product pipeline. Access to patented medicines and global support from the parent company AstraZeneca also provide advantages.

However, some of the larger Indian pharmaceutical companies, such as Sun Pharmaceutical and Cipla, may have a stronger moat due to their larger production capacities, broader product portfolios, and established generic markets. These companies also benefit from extensive distribution networks and a strong presence in international markets, giving them a competitive edge.

Overall, the moat of AstraZeneca Pharma India Limited is less pronounced compared to the leading Indian pharmaceutical companies, but the focus on innovative medicines and support from the global AstraZeneca brand offer some protection against competition.

Revenue Growth: 10.5% (2025) Profit Growth: 8.2% (2025) Research and Development Expenses: 15% of Revenue (2025)

AstraZeneca Pharma India Limited achieved solid revenue growth of 10.5% in 2025, attributed to successful introduction of new drugs and increased demand in various therapy areas. The profit growth of 8.2% reflects efficiency in cost control and successful implementation of growth strategies.

The company continues to heavily invest in research and development, with expenses accounting for 15% of revenue. This indicates that AstraZeneca Pharma India Limited is committed to expanding its product pipeline and developing innovative therapies, which could have long-term positive impacts on growth potential.

Overall, the company demonstrates strong operational performance and a clear strategic focus on innovation and growth. These factors could make it an attractive investment, especially for investors interested in long-term growth.

Dividend Yield: 1.5% (estimated for 2026)
Dividend History: Regular payouts in recent years

AstraZeneca Pharma India Limited has pursued a consistent dividend policy in recent years. The dividend yield is currently estimated at 1.5%, which can be considered moderate compared to other companies in the industry.

The company has regularly distributed dividends in the past, indicating a reliable payout policy. This continuity suggests that AstraZeneca Pharma India Limited will also strive to provide shareholders with a stable dividend in the future, unless significant financial or operational challenges arise.